Product logins

Find logins to all Clarivate products below.


Allergic Respiratory Disorders | Special Topics | US/EU | 2020

Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin E (IgE). Collectively, these types of diseases contribute to substantial morbidity and loss of productivity in affected individuals. Although existing treatments—including nasal and inhaled corticosteroids, bronchodilators, leukotriene antagonists, decongestants, mast cell stabilizers, allergen immunotherapies, and biologics—address the needs of many patients, these therapies prove inadequate for some patients. Asthma therapies such as Roche / Novartis’s well-known anti-IgE agent Xolair are being tested for these disorders. Novel therapies with distinct modes of action and/or targets are also in clinical development to expand treatment options for inadequately controlled patients. The availability of these emerging therapies has the potential to significantly improve patient health outcomes and quality of life.

QUESTIONS ANSWERED

  • What is the landscape for emerging therapies targeting allergic respiratory disorders? What are the key features in ongoing clinical trials?
  • What are interviewed KOLs’ opinions about therapies in development for allergic respiratory disorders?
  • How do experts in the field believe these agents compare with existing therapies?
  • What do thought leaders consider the prevailing areas of unmet need and opportunity in the treatment of various allergic respiratory disorders?

Geographies– United States and EU5

Primary Research– Interviews with ten allergic respiratory disorder experts (allergists, pulmonologists, otolaryngologists) from the United States and Europe

Key Insights Provided

  • Pipeline review: therapies for allergic rhinitis, chronic rhinosinusitis, and nasal polyps.
  • KOLs’ awareness and perceptions of key therapies targeting allergic respiratory disorders.
  • Expectations for emerging therapies versus existing treatments for allergic respiratory disorders.

PRODUCT DESCRIPTION

DRG’s Special Topics reports assess key trends in dynamic disease areas. This report on allergic respiratory disorders will help developers gain needed insight into the clinical development of therapies that could shape the future of this market.

Related Market Assessment Reports

Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…